Hubbry Logo
CytopathologyCytopathologyMain
Open search
Cytopathology
Community hub
Cytopathology
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cytopathology
Cytopathology
Cytopathology
View on Wikipedia
from Wikipedia
A pair of micrographs of a cytopathology specimen showing a 3-dimensional cluster of cancerous cells (serous carcinoma)
An adenocarcinoma with typical features as can be seen on cytopathology

Cytopathology (from Greek κύτος, kytos, "a hollow";[1] πάθος, pathos, "fate, harm"; and -λογία, -logia) is a branch of pathology that studies and diagnoses diseases on the cellular level. The discipline was founded by George Nicolas Papanicolaou in 1928. Cytopathology is generally used on samples of free cells or tissue fragments, in contrast to histopathology, which studies whole tissues. Cytopathology is frequently, less precisely, called "cytology", which means "the study of cells".[2]

Cytopathology is commonly used to investigate diseases involving a wide range of body sites, often to aid in the diagnosis of cancer but also in the diagnosis of some infectious diseases and other inflammatory conditions.[3] For example, a common application of cytopathology is the Pap smear, a screening tool used to detect precancerous cervical lesions that may lead to cervical cancer.

Cytopathologic tests are sometimes called smear tests because the samples may be smeared across a glass microscope slide[4] for subsequent staining and microscopic examination. However, cytology samples may be prepared in other ways, including cytocentrifugation. Different types of smear tests may also be used for cancer diagnosis. In this sense, it is termed a cytologic smear.[5]

Micrograph of a pilocytic astrocytoma, showing characteristic bipolar cells with long pilocytic (hair-like) processes. Smear preparation. H&E stain

Cell collection

[edit]

There are two methods of collecting cells for cytopathologic analysis: exfoliative cytology, and intervention cytology.

Exfoliative cytology

[edit]
A micrograph of an exfoliative cytopathology specimen (Pap test, Pap stain)

In this method, cells are collected after they have been either spontaneously shed by the body ("spontaneous exfoliation"), or manually scraped/brushed off of a surface in the body ("mechanical exfoliation"). An example of spontaneous exfoliation is when cells of the pleural cavity or peritoneal cavity are shed into the pleural or peritoneal fluid. This fluid can be collected via various methods for examination. Examples of mechanical exfoliation include Pap smears, where cells are scraped from the cervix with a cervical spatula, or bronchial brushings, where a bronchoscope is inserted into the trachea and used to evaluate a visible lesion by brushing cells from its surface and subjecting them to cytopathologic analysis.

Intervention cytology

[edit]
Brushes used to collect samples for cytology.

In intervention cytology the pathologist intervenes into the body for sample collection.

Fine-needle aspiration

[edit]
Main article: Fine-needle aspiration

Fine-needle aspiration, or fine-needle aspiration cytology (FNAC), involves the use of a needle attached to a syringe to collect cells from lesions or masses in various body organs, often with the application of negative pressure (suction) to increase yield. FNAC can be performed under palpation guidance (i.e., the clinician can feel the lesion) on a mass in superficial regions like the neck, thyroid or breast; FNAC may be assisted by ultrasound or CAT scan for sampling of deep-seated lesions within the body that cannot be localized via palpation. FNAC is widely used in many countries, but success rate is dependent on the skill of the practitioner. If performed by a pathologist alone, or as team with pathologist-cytotechnologist, the success rate of proper diagnosis is higher than when performed by a non-pathologist.[6] This may be due to the pathologist's ability to immediately evaluate specimens under a microscope and immediately repeat the procedure if sampling was inadequate.

Fine needles are 23 to 27 gauge. Because needles as small as 27 gauge can almost always yield diagnostic material, FNAC is often the least injurious way to obtain diagnostic tissue from a lesion. Sometimes a syringe holder may be used to facilitate using one hand to perform the biopsy while the other hand is immobilizing the mass. Imaging equipment such as a CT scanner or ultrasound may be used to assist in locating the region to be biopsied.

FNAC has become synonymous to interventional cytology.

Sediment cytology

[edit]

For cytology of sediment, the sample is collected from the fixative that was used for processing the biopsy or autopsy specimen. The fixative is mixed properly and taken into a centrifuge tube and is centrifuged. The sediment is used for smearing. These sediments are the cells that are shed by the autopsy and biopsy specimen during processing.

Imprint cytology

[edit]

Imprint cytology is a preparation wherein the tissue of interest touches a glass slide, leaving behind its imprint in the form of cells on the slide.[citation needed] The imprint can subsequently be stained and studied.[citation needed]

Preparation

[edit]

After sampling, two main techniques for processing are used:

  • Smearing of sample directly onto a glass slide.
  • Liquid-based cytology. With the latter, the sample is placed in a liquid that is then processed for further investigation.

Processing of specimens may result in visual artifacts:

  • Smearing of cells across a glass plate may cause smearing artifacts, such as the nuclear smearing of this monocyte, shown as tail-like extension of nuclear material.
    Smearing of cells across a glass plate may cause smearing artifacts, such as the nuclear smearing of this monocyte, shown as tail-like extension of nuclear material.
  • Cervical squamous cells with cornflake artifact, when some mounting medium evaporates before coverslipping.[7]
    Cervical squamous cells with cornflake artifact, when some mounting medium evaporates before coverslipping.[7]

For better visualization of cells and their components, specimens are inked, such as by the Papanicolaou stain, or Romanowsky stain derivatives which include Giemsa, Jenner, Wright, Field, May–Grünwald and Leishman stains.

Parameters

[edit]

The nucleus of the cell is very important in evaluating the cellular sample. In cancerous cells, altered DNA activity can be seen as a physical change in the nuclear qualities. Since more DNA is unfolded and being expressed, the nucleus will be darker and less uniform, larger than in normal cells, and often show a bright-red nucleolus.

While the cytologist's primary responsibility is to discern whether cancerous or precancerous pathology is present in the cellular sample analysed, other pathologies may be seen such as:

  • microbial infections: parasitic, viral, and/or bacterial
  • reactive changes
  • immune reactions
  • cell aging
  • amyloidosis
  • autoimmune diseases

Various normal functions of cell growth, metabolism, and division can fail or work in abnormal ways and lead to diseases.

Cytopathology is best used as one of three tools, the second and third being the physical examination and medical imaging. Cytology can be used to diagnose a condition and spare a patient from surgery to obtain a larger specimen. An example is thyroid FNAC; many benign conditions can be diagnosed with a superficial biopsy and the patient can go back to normal activities right away. If a malignant condition is diagnosed, the patient may be able to start radiation/chemotherapy, or may need to have surgery to remove and/or stage the cancer.

Some tumors may be difficult to biopsy, such as sarcomas. Other rare tumors may be dangerous to biopsy, such as pheochromocytoma. In general, a fine-needle aspiration can be done anywhere it is safe to put a needle, including liver, lung, kidney, and superficial masses.

Proper cytopathology technique takes time to master. Cytotechnologists and cytopathologists can assist clinicians by assisting with sample collection. A "quick read" is a peek under the microscope and can tell the clinician whether enough diagnostic material was obtained. Cytological specimens must be properly prepared so that the cells are not damaged.

Further information about the specimen may be gained by immunohistochemical stains and molecular testing, particularly if the sample is prepared using liquid based cytology. Often "reflex" testing is performed, such as HPV testing on an abnormal pap test or flow cytometry on a lymphoma specimen.

Body regions

[edit]

Cytopathologic techniques are used in the examination of virtually all body organs and tissues:

See also

[edit]

Notes and references

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cytopathology

View on Grokipedia
from Grokipedia
Cytopathology is a of anatomic that focuses on the microscopic examination of cells obtained from bodily fluids, tissues, scrapings, or aspirations to diagnose diseases, particularly cancers, infections, and inflammatory conditions. It differs from by analyzing individual cells or small clusters rather than entire tissue sections, enabling less invasive, rapid, and cost-effective assessments. Developed in the early , cytopathology gained prominence through George Papanicolaou's work on the Pap smear between 1917 and 1928, which revolutionized screening and reduced mortality rates significantly after widespread adoption in the 1960s. The field encompasses several key techniques, including exfoliative cytology, which examines naturally shed or gently collected cells from sources like urine, sputum, or cervical scrapings (e.g., the ); fine-needle aspiration (FNA), a using a thin needle to extract cells from lumps or masses in organs such as the , , or lymph nodes; and abrasive or brush cytology, involving scraping or brushing to gather cells from surfaces like the or bronchi. Samples are typically stained—using methods like Papanicolaou or —and evaluated by pathologists for cellular abnormalities, such as atypical size, shape, or nuclear features indicative of malignancy. Ancillary techniques, including , , and molecular testing, enhance diagnostic accuracy when needed. Cytopathology plays a crucial role in both screening and definitive , often serving as the first-line tool for detecting precancerous or cancerous changes before symptoms arise, as seen in programs for cervical, , and cancers. Its advantages include low complication rates (e.g., clinically significant requiring intervention in <5% of lung FNAs), quick turnaround times, and guidance for subsequent biopsies or treatments, though challenges like false negatives in low-grade lesions require correlation with clinical findings. The discipline was formally recognized with the first U.S. Board certification in 1989, underscoring its evolution into a standardized, teamwork-driven field between pathologists and clinicians.

Introduction

Definition and Scope

Cytopathology is the study of cells obtained from bodily fluids, smears, or aspirates to diagnose diseases, with a primary focus on malignancies, infections, and inflammatory conditions through microscopic examination of cellular features. This discipline enables the identification of pathological changes at the cellular level, serving as a cornerstone of modern diagnostic pathology. The scope of cytopathology extends to diagnostic, screening, and prognostic applications, often utilizing non-invasive or minimally invasive approaches to assess disease states. Core principles revolve around evaluating cellular morphology, including size, shape, and arrangement; cellular architecture, such as clustering patterns; and background elements like inflammatory cells or necrosis, which provide contextual clues to underlying pathology. These evaluations facilitate rapid triage and guide further clinical management, particularly in oncology. In distinction from histopathology, which analyzes intact tissue architecture to understand structural relationships, cytopathology emphasizes individual cells or small clusters, allowing for quicker processing and broader accessibility without requiring surgical biopsies. Key concepts include cellular atypia, characterized by abnormal variations in cell appearance; pleomorphism, reflecting irregular size and shape; and elevated nuclear-cytoplasmic ratios, which signal potential malignancy by indicating disproportionate nuclear enlargement relative to cytoplasm. These indicators form the basis for initial pathological assessments in cytological specimens.

Historical Development

The foundations of cytology trace back to the 17th century with Robert Hooke's observation of cells using early microscopes in 1665, followed by the cell theory proposed by Matthias Schleiden and Theodor Schwann in 1838–1839, establishing cells as the basic units of life. Building on this, the 19th century saw advancements in microscopy and the emergence of cellular pathology through Rudolf Virchow's work; he published Cellular Pathology in 1858, emphasizing that diseases arise from cellular abnormalities and laying the groundwork for later diagnostic cytopathology. Virchow's contributions included early applications of cellular examination to detect parasites, such as his identification of Echinococcus as a causative agent in alveolar echinococcosis during the 1850s. These developments shifted pathology toward cell-centric analysis. Key milestones in the 20th century centered on diagnostic techniques for cancer. In the 1920s and 1930s, George N. Papanicolaou developed a multichromatic staining method that enhanced visualization of cellular morphology, culminating in its formal description in 1942. This innovation enabled the Pap smear's establishment in the 1940s as a screening tool for cervical cancer, following Papanicolaou's 1943 publication with Herbert Traut on diagnosing uterine cancer via vaginal smears, which dramatically reduced mortality through early detection. By the 1950s, aspiration cytology expanded as a minimally invasive diagnostic approach, pioneered in the United States by figures like those at Memorial Hospital, where fine-needle techniques were routinely applied for tumor evaluation. Institutional advancements solidified cytopathology's framework. The International Academy of Cytology was founded in 1957 in Brussels, Belgium, during a Union for International Cancer Control congress, to promote global standards in cytologic practice and research. In the 1960s and 1970s, the World Health Organization introduced histological tumor classifications that influenced cytopathologic diagnostics by standardizing terminology, facilitating international consistency in pathology. The field evolved toward automation and integration in later decades. Flow cytometry was introduced to cytopathology in the 1980s, transitioning from research to clinical applications by enabling rapid analysis of cellular DNA content and immunophenotyping for hematologic malignancies. By the 2000s, molecular diagnostics began integrating with traditional cytology, allowing detection of genetic alterations in cytologic specimens to refine cancer subtyping and guide targeted therapies. As of 2025, advancements include artificial intelligence for automated image analysis and enhanced molecular techniques for precision medicine in cytopathology.

Specimen Collection

Exfoliative Cytology

Exfoliative cytology involves the microscopic examination of cells that are naturally shed or desquamated from epithelial surfaces, allowing for the detection of infections, inflammatory conditions, and neoplastic changes without invasive procedures. The principle relies on collecting these spontaneously exfoliated or mechanically dislodged cells from body cavities, mucosal linings, or fluids, which are then analyzed for cytomorphologic alterations indicative of disease. Common sources for exfoliative cytology include the female genital tract (such as cervical and vaginal samples via Pap smears), the respiratory tract (sputum and bronchial secretions), the urinary tract (voided urine and bladder washings), the oral cavity (buccal scrapings), and body fluids like cerebrospinal fluid. These sites are selected because they yield cells from accessible epithelial linings prone to shedding in response to physiological or pathological processes. The procedure begins with sample collection using appropriate tools, such as wooden spatulas or cotton-tipped applicators for cervical or oral scrapings, brushes for bronchial or bladder sampling, or simple expectoration for sputum. Collected material is immediately smeared onto glass slides or suspended in transport medium and transferred to a fixative to preserve cellular morphology, with details on fixation methods covered elsewhere. This approach offers advantages in patient comfort due to its non-invasive nature and lower cost compared to biopsy techniques, enabling frequent monitoring. Limitations of exfoliative cytology include lower cellularity in some samples, which can lead to inadequate yields for diagnosis, and risks of contamination from adjacent normal tissues or inflammatory cells obscuring pathologic findings. Additionally, it may produce false-negative results in cases of well-differentiated tumors with minimal shedding or false-positives due to reactive atypia from infection or repair processes. Specific examples illustrate its utility: in cervical screening, Pap smears collected via spatula scraping detect squamous intraepithelial lesions with high sensitivity when combined with HPV testing; bronchial brushings during bronchoscopy sample endobronchial lesions to identify lung malignancies, achieving diagnostic accuracy of 80-90% in visible tumors; and voided urine cytology monitors patients with urothelial carcinoma by examining shed transitional cells for atypical features.

Fine-Needle Aspiration Cytology

Fine-needle aspiration cytology (FNAC), also known as fine-needle aspiration (FNA), is a minimally invasive diagnostic technique that uses a thin needle to extract cells from solid lesions or masses for cytological examination. The procedure typically employs needles ranging from 22 to 27 gauge, which allows for precise sampling with minimal tissue disruption. Guidance can be achieved through palpation for superficial lesions or imaging modalities such as ultrasound for deeper or non-palpable targets, with multiple passes often performed to ensure adequate cellular yield. This method contrasts with exfoliative cytology, which relies on naturally shed cells from body fluids or surfaces. FNAC was popularized in the 1960s, particularly for thyroid nodule evaluation, by Scandinavian investigators who demonstrated its efficacy as a safe alternative to open biopsy. It has since become a standard initial diagnostic tool for superficial palpable masses, widely adopted due to its high accuracy and low cost. Common indications include thyroid nodules, breast lumps, and enlarged lymph nodes, where it helps differentiate benign from malignant processes. Rapid on-site evaluation (ROSE) by a cytopathologist is frequently utilized during the procedure to assess sample adequacy in real time, reducing the need for repeat aspirations. The procedure begins with patient preparation, including sterilization of the aspiration site and, for more invasive cases, administration of local anesthesia to minimize discomfort. A syringe attached to the needle creates suction to aspirate cells, though variations exist; the French method, or non-aspiration technique, relies on capillary action by detaching the syringe during sampling to reduce blood contamination and improve cellular preservation. Extracted material is then processed into direct smears for immediate staining or into cell blocks for additional ancillary studies, optimizing diagnostic yield. Complications from FNAC are rare, occurring in less than 1% of cases, and primarily include minor bleeding managed by manual compression, infection at the puncture site, or, in thoracic aspirations, pneumothorax. The low risk profile stems from the small needle size and outpatient nature of the procedure, making it suitable for a broad range of patients, including those on anticoagulants after appropriate evaluation.

Other Collection Techniques

Other collection techniques in cytopathology encompass specialized methods for intraoperative assessment and fluid-based sampling, including imprint cytology, sediment cytology, and endoscopic collections, which complement standard exfoliative and aspiration approaches by enabling rapid or concentrated evaluation of cells from surgical or fluid specimens. Imprint cytology, also known as touch-prep cytology, involves gently pressing a freshly cut surgical specimen onto a glass slide to transfer cells, allowing for immediate microscopic examination after rapid staining. This technique is particularly valuable during intraoperative consultations for tumors, such as ovarian malignancies, where it provides preliminary diagnostic information to guide surgical decisions, with results obtainable in 5-10 minutes. Diagnostic accuracy for imprint cytology in intraoperative settings ranges from 80% to 94.4%, with high specificity often reaching 100% when compared to frozen sections. Sediment cytology focuses on concentrating cells from body fluids, such as pleural or peritoneal effusions, through centrifugation to enhance diagnostic yield in hypocellular samples. The process typically involves centrifuging the fluid at 3000 rpm for 5 minutes to form a cell pellet, which is then resuspended and used to prepare smears via methods like Cytospin (centrifugation at 500-700 rpm for 5 minutes) or liquid-based preparations such as ThinPrep. Cytospin improves cell yield and morphology preservation in low-cellularity fluids, while cell blocks from sediments enable ancillary tests like immunohistochemistry, reducing indeterminate diagnoses from 12 to 6 cases in pleural fluid evaluations across 180 samples. Endoscopic collections, including bronchoscopy washings and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), facilitate targeted sampling from respiratory or gastrointestinal sites. Bronchoscopy involves washing or brushing luminal surfaces to collect exfoliated cells, often prepared as air-dried and alcohol-fixed slides, while EUS-FNA uses real-time ultrasound to aspirate cells from mediastinal lymph nodes or pancreatic masses, with at least one slide per pass for rapid on-site evaluation. These methods achieve diagnostic yields of 50-90% for lung cancer staging and 85-89% sensitivity for solid pancreatic lesions, with specificities up to 99%. These techniques offer high specificity for intraoperative guidance and effective handling of hypocellular fluids, minimizing the need for repeat procedures and supporting decisions like tumor resection extent. For instance, imprint cytology's rapid turnaround aids surgeons in real-time, and sediment methods like Cytospin boost malignancy detection in effusions by preserving architecture for further analysis. Limitations include the necessity for fresh, unfixed tissue to avoid degradation, potential artifacts from mechanical handling or overcrowding in Cytospin preparations, and dependency on operator expertise for endoscopic sampling adequacy. Imprint cytology may falter with fibrous tumors or sampling heterogeneity, while EUS-FNA risks inadequate aspirates in cystic lesions (sensitivity as low as 54%) or tumor seeding in biliary cases. Centrifugation in sediment cytology can distort fragile cells, and all methods require prompt processing to maintain viability for ancillary studies.

Specimen Preparation

Fixation Methods

Fixation in cytopathology serves to preserve cellular morphology and structure immediately following specimen collection, thereby halting autolysis, preventing bacterial degradation, and enabling effective subsequent staining for diagnostic evaluation. This process is essential for maintaining nuclear and cytoplasmic details, with timing being critical—wet-fixed smears require immersion within seconds to minutes, while air-dried preparations must be fixed promptly to avoid distortion. The most widely used fixative for wet-fixed smears is 95% ethanol, which coagulates proteins with minimal shrinkage and preserves chromatin patterns suitable for Papanicolaou staining. For air-dried smears, commonly employed in non-gynecologic cytology, methanol or a methanol-acetone mixture (typically 1:1) is applied to improve cell adherence to slides and enhance Romanowsky-type staining without significant artifact introduction. In contrast, 10% neutral buffered formalin is the standard for cell block preparation from centrifuged sediments, allowing paraffin embedding and compatibility with immunohistochemical and molecular analyses. Fixation techniques vary by specimen type and include direct immersion in coplin jars containing the fixative for wet preparations, or immediate application of alcohol-based spray fixatives (e.g., 95% ethanol or isopropanol) for smears to ensure uniform coverage and prevent evaporation-induced changes. Fluid specimens, such as effusions or aspirates, are typically fixed after concentration via centrifugation, with an equal volume of fixative added to the pellet or supernatant; solid tissues require on-site smearing followed by rapid fixation to handle variability in sample volume and cellularity. These methods ensure consistent preservation across diverse sources, from respiratory lavages to urinary sediments. Key artifacts to avoid include cellular shrinkage and hardening from prolonged exposure to ethanol or formalin (typically beyond 24-48 hours), which can distort nuclear contours and impede staining penetration. Delayed or absent fixation in unfixed samples leads to drying artifacts, such as cytoplasmic vacuolization, nuclear swelling, and loss of fine detail, particularly in air-dried preparations left exposed for more than a few seconds. Optimal fixation duration—often 10-30 minutes for initial immersion—balances preservation with minimal alteration. Contemporary approaches feature liquid-based cytology (LBC) fixatives like PreserveCyt, a methanol-based preservative that suspends cells in a viscous medium, facilitating automated processing, debris removal, and reduced overlapping in non-gynecologic specimens such as fine-needle aspirates. These alternatives improve diagnostic yield by standardizing fixation and enabling ancillary testing, with studies showing enhanced cellular recovery compared to conventional methods.

Staining and Mounting

In cytopathology, staining and mounting are essential steps following fixation to enhance cellular contrast and preserve slides for microscopic examination. These processes involve applying dyes to highlight specific cellular components, such as nuclei, cytoplasm, and extracellular substances, while mounting ensures long-term stability and clarity. Standard protocols prioritize reproducibility and diagnostic accuracy, with variations depending on specimen type and clinical needs. The Papanicolaou (Pap) stain remains the gold standard for routine cytologic evaluation, particularly in gynecologic and nongynecologic specimens, due to its ability to provide detailed nuclear chromatin patterns and cytoplasmic differentiation. Developed by George Papanicolaou in the early 20th century and refined over decades, it employs a sequence of acidic and basic dyes: hematoxylin for basophilic nuclear structures, Orange G-6 (OG-6) for keratinized elements, and eosin azure (EA) for nonkeratinized cytoplasm and nucleoli. The procedure begins with alcohol-fixed smears, followed by hydration, immersion in Harris hematoxylin for 1-3 minutes to stain nuclei blue-black, brief rinsing, differentiation in acid alcohol, bluing in ammonia water, staining in OG-6 for 1-2 minutes to impart orange hues, counterstaining with EA for 2-3 minutes for pink-to-blue cytoplasmic tones, dehydration through graded alcohols, clearing in xylene, and final mounting with a resinous medium like Permount to protect the preparation. This multistep process, typically taking 5-10 minutes manually, yields high-resolution images critical for detecting dysplasia and malignancy. For rapid preliminary assessments, especially in fine-needle aspirations or intraoperative consultations, Romanowsky-type stains like Diff-Quik are preferred for air-dried smears. These modified Giemsa-based methods use a three-step process: fixation in methanol for 15-30 seconds to preserve morphology, staining in eosin Y solution for 15-30 seconds to color cytoplasm pink-to-purple, and immersion in methylene blue for 15-30 seconds to stain nuclei purple, followed by rinsing, air-drying, and optional coverslipping without clearing agents. Diff-Quik offers quick turnaround (under 1 minute) and good contrast for cellular details, though it provides less nuclear nuance than Pap staining. Special stains supplement routine methods to identify specific substances when standard dyes are inconclusive. Mucicarmine, a carmine-aluminum complex, selectively stains intracellular mucin red in adenocarcinomas, aiding differentiation from mesotheliomas or reactive mesothelial cells in pleural effusions. Periodic acid-Schiff (PAS) highlights glycogen and neutral mucins as magenta, useful for detecting fungal elements or cytoplasmic inclusions in respiratory cytology. Immunocytochemical stains, applied post-fixation on destained slides, target antigens like cytokeratins (e.g., AE1/AE3) with chromogenic detection, providing specificity for epithelial origin in metastatic lesions. These ancillary techniques require optimized protocols to avoid antigen retrieval artifacts. Liquid-based cytology (LBC) preparations, such as ThinPrep or SurePath, integrate staining and mounting into automated workflows to minimize obscuring factors like blood or mucus. After collection into preservative fluids (e.g., methanol-based), cells are dispersed, filtered onto a slide or membrane to form a thin monolayer, alcohol-fixed if needed, and stained via modified Pap protocols with reduced volumes for efficiency. Dehydration, clearing, and mounting follow similarly, but LBC enhances uniformity and allows batch processing, improving specimen adequacy in cervical screening compared to conventional smears. Quality control in staining and mounting ensures diagnostic reliability through standardized metrics and monitoring. Laboratories verify even staining intensity, minimal background debris, and artifact-free mounting using control slides run every 8 hours on automated stainers, as mandated by regulatory bodies like the College of American Pathologists. Transition from manual to automated systems has improved consistency, with visual checks for color balance (e.g., crisp nuclear blues in Pap) and slide durability under microscopy. Rescreening rates below 5% indicate effective QC, preventing interpretive errors from uneven dyes or bubbles in the mountant.

Microscopic Evaluation

Cytomorphologic Features

Cytomorphologic evaluation in cytopathology relies on the microscopic assessment of cellular details to identify pathological changes, with nuclear features serving as primary indicators of abnormality. Nuclear size is often enlarged in malignant cells compared to benign counterparts. Chromatin patterns vary significantly: benign cells exhibit fine, evenly dispersed chromatin, while malignant cells display coarse, clumped, or irregularly distributed chromatin, often appearing hyperchromatic due to heightened metabolic demands. Nucleoli in normal or reactive cells are small and inconspicuous, but in malignancy, they become prominent, enlarged, and multiple, signifying active protein synthesis. True intranuclear inclusions can indicate viral infections like herpes simplex virus (HSV) or , appearing as eosinophilic structures within the nucleus and distinguishing infectious from neoplastic processes; pseudoinclusions, formed by cytoplasmic invaginations into the nucleus, are often seen in benign reactive cells or specific tumors such as papillary thyroid carcinoma. Cytoplasmic features provide additional diagnostic clues, particularly in assessing cellular maturity and function. The amount of cytoplasm is typically abundant and basophilic in benign epithelial cells, reflecting organized organelles, whereas malignant cells often show scant, irregular cytoplasm due to dedifferentiation. Granularity varies by cell type; for instance, plasma cells display eccentric nuclei with perinuclear cytoplasmic clearing (Golgi zone), while granular cytoplasm in tumors like granular cell tumors arises from lysosomal accumulation. Vacuoles in the cytoplasm may represent lipid, mucin, or degenerative changes; in malignancy, they often appear as clear, empty spaces indicating secretory dysfunction, as seen in adenocarcinoma cells. A key malignancy indicator is the nuclear-to-cytoplasmic (N/C) ratio, which is low in benign cells but increases in cancers, emphasizing nuclear dominance over cytoplasmic volume. Architectural patterns in cytologic preparations reveal how cells arrange and interact, aiding in lesion characterization. Benign cells often form orderly monolayer sheets or cohesive clusters with uniform spacing, while malignant cells exhibit disordered three-dimensional clusters, papillary fronds with fibrovascular cores, or acinar formations mimicking glandular architecture. The background material is informative: clean or proteinaceous in benign samples, but malignant specimens frequently show necrosis (amorphous debris), inflammation (neutrophils, lymphocytes), or tumor diathesis (blood-tinged granular material), signaling aggressive growth. Distinguishing benign from malignant cells hinges on morphologic uniformity versus variability. Benign populations demonstrate monomorphism, with cells of similar size, shape, and staining, lacking atypical mitoses; this uniformity reflects controlled proliferation. Malignant indicators include pleomorphism, where cells vary markedly in size and contour, often with irregular nuclear membranes, prominent nucleoli, and abnormal mitoses (e.g., tripolar or asymmetrical figures), indicating genetic instability and uncontrolled division. Artifacts can mimic or obscure true pathology, requiring careful interpretation. Overlapping cells in crowded preparations may simulate nuclear enlargement or irregularity, but even distribution across multiple fields differentiates this from genuine atypia. Crush artifacts, resulting from mechanical trauma during smearing, cause nuclear molding, chromatin smudging, or cytoplasmic streaming, potentially resembling small cell carcinoma; correlation with clinical context and ancillary stains helps distinguish these from authentic features.

Diagnostic Parameters

In cytopathology, diagnostic parameters encompass standardized criteria for evaluating cellular features to classify specimens as benign, atypical, or malignant. Key parameters include cellularity, which assesses the overall number of cells present—adequate cellularity is typically required for reliable interpretation, such as at least 5,000 squamous cells in liquid-based cervical preparations or 6-10 groups of follicular cells in thyroid fine-needle aspirations. Degree of atypia evaluates nuclear changes like enlargement, hyperchromasia, irregular contours, and increased nuclear-to-cytoplasmic ratios, with mild atypia suggesting reactive processes and severe atypia indicating dysplasia or neoplasia. Mitotic activity is quantified by counting abnormal or atypical mitoses, which, when elevated (e.g., >5 per 10 high-power fields in some contexts), supports a malignant diagnosis, though it must be interpreted alongside architectural patterns. Quantitative measures like DNA ploidy, determined via image analysis of Feulgen-stained smears, detect aneuploidy as a marker of genomic instability; diploid patterns correlate with benign lesions, while aneuploidy increases suspicion for malignancy. Reporting systems provide structured frameworks for consistent classification. The Bethesda System for Reporting Cervical Cytology, established in 1988 and updated in 2014, categorizes findings into six tiers: Negative for Intraepithelial Lesion or Malignancy (NILM), Atypical Squamous Cells of Undetermined Significance (ASC-US), Atypical Squamous Cells cannot exclude High-Grade Squamous Intraepithelial Lesion (ASC-H), Low-Grade Squamous Intraepithelial Lesion (LSIL), High-Grade Squamous Intraepithelial Lesion (HSIL), and Squamous Cell Carcinoma, with associated risks of high-grade disease ranging from <1% for NILM to 60-70% for HSIL. Similarly, the Bethesda System for Reporting Thyroid Cytopathology, revised in 2023, uses six categories: Nondiagnostic, Benign, Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS), Follicular Neoplasm/Suspicious for Follicular Neoplasm, Suspicious for Malignancy, and Malignant, with malignancy risks from <3% for Benign to 97-99% for Malignant. These systems emphasize adequacy assessment and include explanatory notes to guide clinical management, reducing interobserver variability. Cytopathology demonstrates variable performance in malignancy detection, with overall sensitivity ranging from 70% to 90% and specificity exceeding 95% across sites like breast, thyroid, and lung, though false negatives (5-15%) often arise from sampling errors in low-cellularity specimens or obscured malignant cells. For instance, in thyroid fine-needle aspiration, sensitivity is approximately 89% with 98% specificity, while cervical cytology achieves 70-85% sensitivity for high-grade lesions. Integration of ancillary tests enhances accuracy; flow cytometry on cytologic suspensions analyzes lymphocyte subsets in lymph node aspirates, identifying clonal populations in non-Hodgkin lymphoma with >90% specificity, and supports triage algorithms like those in the Bethesda cervical system, where ASC-US prompts HPV testing to stratify risk. Quality assurance in cytopathology involves proficiency testing mandated by regulations like CLIA '88, requiring laboratories to achieve >90% accuracy on gynecologic slides, and rescreening of negative cases to detect discrepancies. Error rates, including 5-10% discordance between cytology and subsequent (primarily false negatives due to ), are monitored through studies and external audits, ensuring interpretive reliability and minimizing diagnostic pitfalls.

Clinical Applications

Respiratory and Thoracic Systems

Cytopathology plays a crucial role in diagnosing diseases of the respiratory and thoracic systems, particularly through the examination of exfoliated cells from , bronchial washings, and pleural effusions, as well as (FNA) of nodules. cytology is a non-invasive method suitable for detecting central airway lesions, with a pooled sensitivity of 66% and specificity of 99%, though yields improve to 60-80% for central tumors when multiple samples are analyzed. Bronchial washings and brushings, obtained via , enhance diagnostic accuracy for endobronchial abnormalities, achieving sensitivities of 83-100% in suspicious cases under the (WHO) reporting system for cytopathology. Pleural effusions are commonly evaluated for metastatic involvement or primary pleural malignancies, while FNA, often CT-guided, targets peripheral nodules with high specificity for malignancy detection. Key diagnoses in respiratory cytopathology include non-small cell lung carcinoma (NSCLC), distinguished by subtypes such as and . often presents with three-dimensional glandular clusters, vacuolated cytoplasm, and prominent nucleoli in cytologic smears, aiding subtyping with a positive predictive value of 92%. features keratinized orangeophilic cells, dense cytoplasm, and tadpole-shaped forms, particularly in central lesions sampled by or bronchial cytology. Malignant in pleural effusions shows epithelioid cells with abundant vacuolated cytoplasm forming morules or sheets, often requiring to differentiate from , which is the most common cause of malignant pleural effusions. Infections such as are identified by granulomatous inflammation with necrotic debris and acid-fast bacilli in bronchial washings or , with cytology contributing to rapid presumptive diagnosis in high-prevalence areas. Benign findings in respiratory cytology include ciliated bronchial epithelial cells with terminal bars and goblet cells, indicating reactive changes rather than neoplasia. In asbestosis-related cases, ferruginous bodies—golden-brown, beaded fibers coated with iron and protein—are in sputum or lavage specimens, linking exposure to . The WHO system categorizes such specimens as "benign" when these features predominate without atypical cells. In screening high-risk smokers, low-dose CT identifies nodules that prompt cytologic evaluation via FNA or , improving early detection yields in central lesions up to 80%. However, challenges persist, including obscuring elements like thick in bronchial washings that reduce cellular yield and require liquid-based preparation for better smear quality. Small cell carcinoma exhibits low sensitivity on cytology due to its crush artifact and sparse material, often necessitating core biopsy for confirmation despite high specificity in well-sampled cases.

Gastrointestinal and Genitourinary Systems

Cytopathology plays a crucial role in diagnosing diseases of the gastrointestinal () and genitourinary (GU) systems through targeted sampling techniques that provide cellular material for microscopic evaluation. In the GI tract, endoscopic methods such as brushings and (FNA) enable the assessment of mucosal and submucosal lesions, while in the GU system, exfoliative cytology from urine and percutaneous FNA of renal masses offer non-invasive or minimally invasive diagnostic insights. These approaches are particularly valuable for detecting malignancies like esophageal carcinoma, pancreatic adenocarcinoma, , urothelial carcinoma, and , with diagnostic yields influenced by lesion accessibility and cellularity. Esophageal brush cytology, performed during endoscopy, collects exfoliated cells from the esophageal lining to detect squamous cell carcinoma and adenocarcinoma, especially in high-risk populations such as those with Barrett's esophagus. This technique demonstrates moderate sensitivity for malignancy detection, with accuracy improved when combined with biopsy, as brushing alone may miss deeper lesions due to sampling limitations. For pancreatic lesions, endoscopic ultrasound-guided FNA (EUS-FNA) is the standard for sampling solid masses and cysts, yielding a diagnostic accuracy of approximately 80% for pancreatic ductal adenocarcinoma through identification of atypical ductal cells with nuclear enlargement and irregular chromatin. In cystic lesions, a mucinous background with extracellular mucin and columnar epithelial cells suggests a mucinous cystic neoplasm or intraductal papillary mucinous neoplasm, aiding in risk stratification for malignancy. Bile duct washings or brushings, often obtained during endoscopic retrograde cholangiopancreatography, are used to diagnose cholangiocarcinoma, showing high specificity (up to 99%) but modest sensitivity (around 53-75%) due to challenges in sampling strictures and desmoplastic reactions that limit cellular yield. In the GU system, urine cytology remains a cornerstone for detecting urothelial carcinoma, particularly through bladder washings or voided specimens, where high-grade atypia—characterized by hyperchromatic nuclei, irregular nuclear membranes, and high nuclear-to-cytoplasmic ratios—is a hallmark of high-grade urothelial carcinoma (HGUC). The Paris System for Reporting Urinary Cytology standardizes interpretation, categorizing specimens as negative for HGUC, atypical urothelial cells, suspicious for HGUC, or positive for HGUC, with improved sensitivity (up to 90%) for high-grade lesions but notable challenges in identifying low-grade urothelial lesions due to subtle atypia and overlapping benign changes. Renal FNA, typically image-guided, evaluates solid and cystic kidney masses, achieving high diagnostic accuracy (91-95%) and sensitivity (90-97%) for renal cell carcinoma by revealing clear cell clusters with prominent nucleoli and vascular cores. For screening, anal Pap testing mirrors cervical cytology to detect HPV-related anal intraepithelial neoplasia or dysplasia in high-risk groups like those with HIV, identifying squamous atypia indicative of high-grade squamous intraepithelial lesions with sensitivity enhanced by HPV co-testing. Stool-based cytology for colorectal cancer screening has a limited role, hampered by poor cell preservation and low yield of diagnostic epithelial cells amidst debris, rendering it less effective compared to molecular stool tests.

Other Body Regions

In cytopathology of the head and neck, oral scrapings via brush cytology serve as a noninvasive method for detecting , particularly in high-risk patients, by identifying dysplastic epithelial cells with high sensitivity approaching 90% and specificity around 85%. This technique is well-tolerated and aids in early screening of oral lesions, though superficial sampling can lead to false negatives. (FNA) of salivary glands is a cornerstone for evaluating neoplasms, with the Milan System providing standardized reporting categories to stratify risk, such as nondiagnostic, benign, or suspicious for malignancy; however, overlapping morphologic features in pleomorphic adenomas and carcinomas pose diagnostic challenges, often necessitating ancillary molecular testing for fusions like PLAG1. Breast cytopathology includes nipple discharge analysis, which detects intraductal pathologies like papillomas or through cytologic features such as erythrocytes, hemosiderin-laden macrophages, and pseudo-papillary clusters of ductal cells; bloody discharge raises suspicion for in about 4% of cases, though the cytology demonstrates low sensitivity (41-85%), with challenges such as degenerative in benign lesions mimicking cancer, while maintaining high specificity (97%). For palpable lumps, FNA differentiates —characterized by hypercellular smears with cohesive epithelial sheets in a staghorn pattern, bipolar naked nuclei, and fibromyxoid stroma—from ductal , which exhibits dyshesive pleomorphic cells with high nuclear-to-cytoplasmic ratios, prominent nucleoli, and absence of myoepithelial cells; false-negative rates for range from 1.2-10.6%, often due to sampling errors in low-grade tumors. Ultrasound guidance enhances FNA adequacy in lesions to rates of 87-93%, minimizing repeats. Thyroid FNA employs for Reporting, which classifies aspirates into six categories based on cytomorphologic features, with associated risks of ranging from 0-3% for benign to 97-99% for malignant; this system guides management, such as repeat FNA for nondiagnostic cases or surgery for suspicious ones. Papillary thyroid carcinoma is typified by orphan Annie eye nuclei, intranuclear pseudoinclusions, and psammoma bodies—concentric calcified structures within papillary fronds—though these bodies occur rarely in benign conditions like follicular nodular disease or Hashimoto , complicating exclusivity. Ultrasound-guided FNA achieves adequacy rates up to 94% in nodules, supporting precise risk stratification. Site-specific challenges include cystic degeneration obscuring features and the need for multiple passes in microfollicular lesions. Central nervous system (CNS) cytopathology relies on cerebrospinal fluid (CSF) examination for leptomeningeal metastasis, where malignant cells from primaries like breast or lung cancer appear as atypical clusters with high nuclear irregularity; diagnostic yield improves with elevated CSF cell counts (seen in 79-92% of cases), but sensitivity is limited by intermittent shedding and normal MRI in up to 38%, requiring multiple lumbar punctures. Intraoperative brain imprints, prepared by touching fresh tissue to slides for rapid smearing and , facilitate real-time of tumors like gliomas (fibrillary processes) or meningiomas (whorled epithelioid cells), with accuracy exceeding 80% for common CNS neoplasms and aiding surgical margins; challenges include tissue friability causing artifactual distortion and the need for immediate interpretation to avoid delays. Soft tissue cytopathology via FNA triages sarcomas by identifying spindle or pleomorphic cells in myxoid or collagenous matrices, enabling distinction from benign mimics like ; however, remains challenging without (IHC), with accuracy limited to 63% for primaries due to cytologic overlap among entities like and , and reported rates as low as 21-74% in varied cohorts. Ancillary cell block preparation for IHC is essential, as pure cytology often yields only 50-70% precision, particularly for small biopsies in heterogeneous tumors. Guidance enhances yield but cannot fully overcome sampling variability in deep lesions.

Advanced Techniques

Automation and Digital Imaging

Digital pathology in cytopathology encompasses the use of computerized systems to scan, analyze, and interpret cytological specimens, primarily through whole-slide imaging (WSI) scanners that digitize entire slides for virtual microscopy. These scanners capture high-resolution images, typically at 40x magnification equivalent to 0.25 μm per pixel, enabling detailed visualization of cellular morphology without physical slide handling. WSI facilitates remote access, education, and integration with artificial intelligence (AI) for enhanced diagnostic workflows, particularly in handling the heterogeneous cell distribution and three-dimensional clusters common in cytology preparations. Automated screening systems represent a key advancement in cytopathology, streamlining the triage of high-volume samples such as Pap tests. The BD FocalPoint GS Imaging System, FDA-cleared in 2008, assists in primary screening of SurePath slides by ranking them based on abnormality likelihood and highlighting up to 10 fields of view for review, demonstrating a 19.6% increase in sensitivity for high-grade (HSIL) and above compared to manual methods (85.3% vs. 65.7%). Similarly, the ThinPrep Imaging System, cleared in 2003, automates the selection of 22 fields of view on ThinPrep slides, maintaining equivalent sensitivity for HSIL+ detection while improving specificity by 0.2%. Recent AI algorithms, such as those in BestCyte and CytoProcessor systems, achieve sensitivities of 93% to 100% for HSIL in screening in various studies, reducing the need for full manual review of normal cases. Telecytology leverages digital transmission for remote rapid on-site evaluation (), allowing real-time assessment of adequacy via platforms like dynamic video streaming or static WSI. This approach achieves over 90% concordance in adequacy rates for procedures such as and FNAs, enabling expert consultation without on-site presence. In underserved areas, telecytology bridges access gaps by facilitating diagnostics in resource-limited settings, where low-cost portable scanners and mobile integration support high-quality remote evaluations during pandemics or in rural clinics. The primary advantages of and include substantial workload reduction and interpretive standardization. Implementation of digital systems has been shown to decrease pathologist workload by an average of 29.2%, with reductions exceeding 50% during peak periods, alongside improvements from 10.58 days to 6.86 days. These tools standardize slide review by minimizing inter-observer variability through consistent protocols and AI-assisted , enhancing overall efficiency in high-throughput laboratories. Despite these benefits, limitations persist, including high initial costs for scanners and , which can delay adoption in smaller facilities. Regulatory hurdles require FDA clearance, with key systems approved since the early , and validation studies report 90% to 98.3% diagnostic concordance between digital and manual methods, though challenges like multi-plane focusing for cytology clusters can extend scan times and file sizes up to 8 GB.

Molecular Cytopathology

Molecular cytopathology integrates genetic, proteomic, and other ancillary tests on cytologic samples to enhance diagnostic precision and guide targeted therapies in oncology. This approach leverages minimally invasive specimens, such as fine-needle aspirations (FNAs) or body fluids, to detect molecular alterations that inform prognosis and treatment selection. By analyzing DNA, RNA, or proteins at the cellular level, it bridges traditional morphology with precision medicine, particularly in cancers where tissue biopsies are challenging. Key techniques include (FISH) for detecting chromosomal and rearrangements. For instance, the UroVysion uses multitarget, multicolor FISH to identify of chromosomes 3, 7, and 17, as well as homozygous deletion of 9p21 ( locus), in samples for surveillance. This method requires scoring at least 25 non-overlapping urothelial cells, with positivity defined as four or more cells showing in two or more probes. Another foundational technique is (PCR) for viral DNA detection, such as high-risk human papillomavirus (HPV) in cervical cytology. Real-time PCR , like those targeting HPV-16 and HPV-18, achieve high sensitivity (up to 96.7%) in liquid-based cervical samples, enabling of atypical squamous cells and identification of oncogenic risk. Applications extend to oncogenic driver mutations in solid tumors, particularly via FNA samples. Detection of (EGFR) mutations, such as exon 19 deletions or L858R substitutions, in non-small cell lung carcinoma (NSCLC) FNAs uses amplification-refractory mutation system PCR (ARMS-PCR), with success rates exceeding 80% in cytologic material and concordance of 90-95% with histologic samples. Similarly, (ALK) rearrangements are identified via break-apart FISH probes in endobronchial ultrasound-guided FNA (EBUS-TBNA) specimens, where positivity requires split signals in at least 15% of tumor cells, supporting therapy in 5-7% of NSCLC cases. Next-generation sequencing (NGS) on cell blocks from cytologic samples enables comprehensive profiling for multiple actionable alterations, including EGFR, ALK, ROS1, and , with 94-95% success rates in small biopsies and identification of therapeutic targets in up to 50% of advanced NSCLC patients. As of 2025, NGS success rates in cytology specimens for NSCLC have reached 98.4% in multicenter validations, identifying actionable alterations in over 50% of cases in some cohorts. Effective molecular testing on cytologic samples demands adequate cellularity, typically 100-500 tumor cells minimum depending on the assay, to ensure sufficient nucleic acid yield for reliable extraction. Liquid-based preparations are preferred for DNA and RNA isolation, as they minimize cellular degradation and contamination compared to conventional smears, facilitating downstream applications like PCR or NGS. Since the 2010s, molecular cytopathology has shifted toward companion diagnostics, aligning tests with FDA-approved therapies like EGFR tyrosine kinase inhibitors. This era saw NGS adoption for multiplexed mutation detection, with sensitivities of 80-95% for actionable alterations in cytology-derived cell blocks, improving personalized treatment outcomes in resource-limited settings. Challenges persist, including contamination risks in small-volume samples from FNAs or effusions, which can dilute tumor DNA and yield false negatives if tumor cellularity falls below 10-20%. Cost-effectiveness remains a barrier, with individual tests ranging from $500 for targeted PCR to $2,000 for comprehensive NGS panels, necessitating prioritization for high-yield cases to balance clinical utility and economic constraints.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3507055/
  2. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/cytology
  3. https://my.clevelandclinic.org/health/diagnostics/21714-cytology
  4. https://www.cancer.org/cancer/diagnosis-staging/tests/biopsy-and-cytology-tests/cytology-types.html
  5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507055/
  6. https://www.unmc.edu/alliedhealth/career-exploration/cyto.html
  7. https://training.seer.cancer.gov/abstracting/procedures/pathological/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3809146/
  9. https://www.researchgate.net/profile/Murat-Durdu/publication/331333693_History_of_Cytology/links/602a8f3fa6fdcc37a82bf2d7/History-of-Cytology.pdf
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC5665122/
  11. https://stacks.cdc.gov/view/cdc/16733/cdc_16733_DS1.pdf
  12. https://pathology.duke.edu/education/graduate-program-pathobiology-and-translational-biosciences
  13. https://karger.com/acy/article/61/4-5/266/9352/Inception-and-Development-of-the-Papanicolaou
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC4613936/
  15. https://www.annclinlabsci.org/content/38/3/296.long
  16. https://www.cytology-iac.org/membership-and-the-iac/about-the-iac/history/
  17. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/pathological-staging-and-classification-systems
  18. https://www.tandfonline.com/doi/pdf/10.1080/08998280.1989.11929708
  19. https://www.researchgate.net/publication/8259913_Molecular_diagnostic_cytopathology_Definitions_scope_and_clinical_utility
  20. https://pubmed.ncbi.nlm.nih.gov/33826796/
  21. https://www.ncbi.nlm.nih.gov/books/NBK287/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC7121370/
  23. https://www.ncbi.nlm.nih.gov/books/NBK557486/
  24. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncy.21742
  25. https://www.endotext.org/wp-content/uploads/pdfs/fine-needle-aspiration-biopsy-of-the-thyroid-gland.pdf
  26. https://www.researchgate.net/publication/327062968_Fine_Needle_Aspiration_Cytology_FNAC_-_Review_Article
  27. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncy.21256
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC12134854/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC5885608/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC9079316/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7315917/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC6032705/
  33. https://www.scacm.org/HandoutsWrkshp2017/LaSala_Rocco-SCACM_2017_Workshop-Cyto_Histo_Intro.pdf
  34. https://tpmap.org/submission/index.php/tpm/article/view/698/567
  35. https://medicine.uams.edu/pathology/divisions/anatomic-pathology/cytopathology/
  36. https://link.springer.com/chapter/10.1007/978-981-10-8252-8_13
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC6953932/
  38. https://www.cap.org/member-resources/articles/doing-a-lot-with-a-little-molecular-testing-on-cytology-specimens
  39. https://journals.lww.com/jocy/fulltext/2013/30040/cytological_artifacts_masquerading_interpretation.5.aspx
  40. https://basicmedicalkey.com/laboratory-techniques/
  41. https://www.pathologyoutlines.com/topic/cytopathologyliquidbased.html
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10067664/
  43. https://ihcworld.com/2024/01/26/papanicolaou-stain-pap-stain-protocol/
  44. https://microbenotes.com/papanicolaou-staining/
  45. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/249/188/procedure-ht40-papanicolaoustainingsystem-ms.pdf?srsltid=AfmBOoro1yKBfl1b-Y8M527KGfU0ezvRSfP2k0fRd2gGpvGHjLY8Ia4
  46. https://cytojournal.com/nuances-of-the-papanicolaou-stain/
  47. https://www.sciencedirect.com/topics/medicine-and-dentistry/romanowsky-stain
  48. https://ihcworld.com/2024/01/26/diff-quick-diff-quik-staining-protocol/
  49. https://pubmed.ncbi.nlm.nih.gov/12075519/
  50. https://www.leicabiosystems.com/us/knowledge-pathway/special-stain-techniques-for-the-evaluation-of-mucins/
  51. https://www.pathologyoutlines.com/topic/stainsmucins.html
  52. https://www.captodayonline.com/cytopathology-in-focus-special-stains-in-the-cytology-laboratory/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC9345114/
  54. https://www.sciencedirect.com/topics/medicine-and-dentistry/liquid-based-cytology
  55. https://www.pathologyoutlines.com/topic/managementlabappdigpathqa.html
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC12087438/
  57. https://www.dvm360.com/view/diagnostic-cytology-basics-proceedings
  58. https://www.pathologyoutlines.com/topic/cytopathologylungmalignant.html
  59. https://learn.mghpathology.org/index.php/mgh:cyto-1-2
  60. https://journals.sagepub.com/doi/10.1177/1066896910385342
  61. https://www.ncbi.nlm.nih.gov/books/NBK9553/
  62. https://pubmed.ncbi.nlm.nih.gov/11748580/
  63. https://todaysveterinarypractice.com/cytology/cytology-of-neoplasia-an-essential-component-of-diagnosis/
  64. https://eclinpath.com/cytology/cytology-interpretation/
  65. https://onlinelibrary.wiley.com/doi/10.1002/dc.22842
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC3945624/
  67. https://www.pathologyoutlines.com/topic/cervixcytologybethesda.html
  68. https://www.pathologyoutlines.com/topic/thyroiddiagnostic.html
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC9168399/
  70. https://www.liebertpub.com/doi/full/10.1089/thy.2023.0141
  71. https://www.sciencedirect.com/science/article/pii/S1110036215000540
  72. https://link.springer.com/article/10.2325/jbcs.14.388
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC5590370/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC1481513/
  75. https://academic.oup.com/ajcp/article-pdf/115/3/338/24981074/ajcpath115-0338.pdf
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC7319090/
  77. https://journal.chestnet.org/article/S0012-3692%2815%2932989-5/abstract
  78. https://www.pathologyoutlines.com/topic/cytopathologylungWHO.html
  79. https://www.xiahepublishing.com/2771-165X/JCTP-2023-00068
  80. https://resolve.cambridge.org/core/services/aop-cambridge-core/content/view/0B82B43442DE7E4CF1B7A1FD9981127E/9781139023351c1_p1-20_CBO.pdf/introduction-to-lung-cytopathology-and-small-tissue-biopsy.pdf
  81. https://pathology.ubc.ca/files/2012/06/LUNGCYTOATLAS_NGK1.pdf
  82. https://www.pathologyoutlines.com/topic/pleuramesovsadeno.html
  83. https://www.sciencedirect.com/topics/nursing-and-health-professions/asbestos-body
  84. https://journals.lww.com/jocy/fulltext/2017/34030/liquid_based_and_conventional_cytology_for.1.aspx
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2872744/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8887942/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC11683391/
  88. https://file.pathology.ubc.ca/BreastCytoBook.pdf
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC3108472/
  90. https://ajronline.org/doi/10.2214/AJR.16.17157
  91. https://endocrinologia-chuc.org/wp-content/uploads/2022/06/The-2017-Bethesda-System-for-Reporting-Thyroid-Cytopathology_Thyroid-2017.pdf
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC11564275/
  93. https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2025/09000/comparison_of_fine_needle_aspiration_of_thyroid.8.aspx
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC6710356/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10911881/
  96. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(20001025)90:5%3C292::AID-CNCR5%3E3.0.CO;2-8
  97. https://www.sciencedirect.com/science/article/pii/S2153353925000318
  98. https://www.sciencedirect.com/science/article/pii/S1756231721001183
  99. https://www.accessdata.fda.gov/cdrh_docs/pdf/P950009S008c.pdf
  100. https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020002c.pdf
  101. https://karger.com/acy/article/doi/10.1159/000546182/929069/Artificial-Intelligence-in-Gynecologic-Cytology
  102. https://www.mdpi.com/2227-9032/13/6/657
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC12088733/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC7698715/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC6425779/
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC8100858/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837376/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC5379858/
  109. https://www.ajmc.com/view/an-overview-of-nsclc-and-actionable-mutations
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC12512683/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC9636510/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC10098847/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC6962840/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC8451925/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC4367742/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC11886603/
Add your contribution
Related Hubs
User Avatar
No comments yet.